Russia to increase public procurement of drugs against rare diseases

13 January 2022
russia_roubles_rubles_money_big

The Russian government will consider increasing funding of “Circle of Kindness,” the national public foundation specializing on the procurement of drugs for the treatment of children with rare diseases, reports The Pharma Letter’s local correspondent.

As part of these plans, its funding could be increased by at least 6 billion roubles ($80 million) a year, while the number of recipients, will be expanded. The latter initiative has recently been put forward by Russia’s President Vladimir Putin.

So far, the fund has specialized on the procurements of high-priced drugs for the treatment of children with rare diseases, such as spinal muscular atrophy (SMA). However, as part of state plans it is beginning procurement of drugs also for adults.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical